Mekonos, a biotech company launching the first-of-its kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has completed a $4.6 million financing round. Mekonos will use the new capital to accelerate the SoC platform for its current and new commercial partnerships. The SoC platform, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The platform is scalable across all cell types and has shown to be a high yield solution for partners